Micro-Invasive Glaucoma Surgery (MIGS)

The treatment for glaucoma has come a long way. Today’s advanced technologies and procedures make it possible to diagnose and successfully manage this progressive disease. And while the overall goal of treatment has always remained the same — reducing intraocular pressure (IOP) and glaucomatous progression — Micro-Invasive Glaucoma Surgery (MIGS) is quickly becoming a widely accepted approach for treating mild-to-moderate glaucoma. 1 And the approval of iStent inject® transformed MIGS again, as the smallest device known to be implanted in the human body.

Glaucoma Therapy Advances

Glaucoma is primarily managed with prescription eye drops. If a patient’s glaucoma progresses or the patient stops responding to the eye drops, a surgical solution is offered. These surgical solutions are often highly invasive, require long recovery times, and could result in long-term complications.

As technology has progressed, less invasive techniques have emerged that have improved the safety profile for glaucoma surgery. This opened more surgical options for patients interested in effective glaucoma management which does not rely solely on the continuous use of prescription medication.

A Revolution in Glaucoma Therapy

With the FDA approval of the iStent®, Micro-Invasive Glaucoma Surgery (MIGS) became a preferred approach to glaucoma management for many eye care professionals and their patients with mild-to-moderate glaucoma. 1 And the approval of iStent inject® transformed MIGS again, as the smallest device known to be implanted in the human body.

Now, with the FDA approval of iStent inject® W – the next-generation Glaukos trabecular micro-bypass technology – Glaukos continues to advance the standard of care for glaucoma patients.

Performed at the time of cataract surgery, iStent inject® W is built on a proven platform of technology shown to allow patients to achieve normal eye pressure after the procedure, with an excellent overall safety profile.2, 3

iStent inject® W may also reduce patients’ need for medications as determined by an eye care professional. The majority of patients who received iStent inject® in the U.S. pivotal trial were medication-free at 23 months. 2 Other benefits associated with Glaukos trabecular micro-bypass technologies include:

• Minimally traumatic to delicate eye tissue
• Effectively lowers IOP
• Excellent safety profile
• Rapid recovery

The iStent inject® W Procedure

Important Safety Information »

1. Market Scope, 2017 Glaucoma Surgical Device Report
2. Samuelson TW, Sarkisian SR, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract. Ophthalmology. Jun 2019;126(6):811-821
3. Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. Ophthalmol Ther. 2018 Dec;7(2):405-415.

Speak with a Physician Today

Help is right around the corner. Leading eye professionals across the country offer iStent inject® W for the treatment and control of eye pressure associated with mild-to-moderate open-angle glaucoma, and are available to answer your questions. Find out if you are a candidate for iStent inject® W by talking with an iStent inject® W physician in your area today.

Find a Physician